Aevi Genomic Medicine Shares Outstanding 2012-2018 | GNMX

Current and historical number of shares outstanding for Aevi Genomic Medicine (GNMX) from 2012 to 2018. Diluted shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options.
Aevi Genomic Medicine Annual Shares Outstanding
(Millions of US $)
2017 $42
2016 $35
2015 $27
2014 $19
2013 $18
2012 $11
2011 $8
Aevi Genomic Medicine Quarterly Shares Outstanding
(Millions of US $)
Q2 2018 $59
Q1 2018 $59
Q4 2017 $42
Q3 2017 $37
Q2 2017 $37
Q1 2017 $37
Q4 2016 $35
Q3 2016 $37
Q2 2016 $33
Q1 2016 $33
Q4 2015 $27
Q3 2015 $25
Q2 2015 $25
Q1 2015 $25
Q4 2014 $19
Q3 2014 $19
Q2 2014 $19
Q1 2014 $19
Q4 2013 $18
Q3 2013 $18
Q2 2013 $18
Q1 2013 $16
Q4 2012 $11
Q3 2012 $12
Q2 2012 $10
Q1 2012 $10
Q4 2011 $8
Q3 2011 $10
Q2 2011 $9
Q1 2011 $5
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.069B $0.000B
Aevi Genomic Medicine Inc. is focused on genomic medicine. The Company focuses on translating genetic discoveries into novel therapies. Its product candidates include AEVI-001 and AEVI-002 which are in clinical trial stage. Aevi Genomic Medicine Inc., formerly known as Medgenics Inc., is based in WAYNE, United States.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $63.001B 10.81
Teva Pharmaceutical Industries (TEVA) Israel $24.629B 6.88
Mylan (MYL) United Kingdom $19.669B 8.37
Bausch Health Cos (BHC) Canada $7.633B 5.70
Dr Reddy's Laboratories (RDY) India $5.610B 25.06
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.887B 4.91
Akorn (AKRX) United States $2.382B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.339B 25.03
Assembly Biosciences (ASMB) United States $0.930B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.824B 118.80
CymaBay Therapeutics (CBAY) United States $0.723B 0.00
Voyager Therapeutics (VYGR) United States $0.626B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.610B 0.00
Homology Medicines (FIXX) United States $0.607B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.589B 0.00
Corium (CORI) United States $0.324B 0.00
Teligent (TLGT) United States $0.228B 0.00
Sol-Gel Technologies (SLGL) Israel $0.119B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.111B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.071B 0.00
Versartis (VSAR) United States $0.065B 0.00
Evoke Pharma (EVOK) United States $0.041B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.020B 0.00
Acasti Pharma (ACST) Canada $0.017B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00